Medicalgorithmics S.A. — Share Issue/Capital Change 2026

Jan 21, 2026

Report Content Receipt by the Company of an offer from BioFund Capital Management LLCspecifying the issue price of PLN 33 per share in connection with theconversion of loan debt into shares of the Company

Current Report 6/2026

Legal basis: Article 17(1) MAR - inside information.

The Management Board of Medicalgorithmics S.A., with its registeredoffice in Warsaw (the "Issuer" or the "Company"), hereby announces that,in connection with negotiations regarding the conversion of theliabilities arising from the loan agreement dated 29 November 2024, asamended by the annex dated 15 April 2025 - i.e., the principal andaccrued interest - into shares of the Company, to which the Company wasinvited by the lender and shareholder, BioFund Capital Management LLC("BioFund"), as disclosed in Current Report 5/2026, the Company hasreceived from BioFund an offer for BioFund to subscribe for shares ofthe Company under the aforementioned conversion, at an issue price ofPLN 33 per share.

The offer also indicates that the proposed debttoequity conversionwill require obtaining an independent valuation (fairness opinion)confirming that the transaction is conducted on market terms, and thatthe process should comply with all applicable local regulations,including the Polish Commercial Companies Code and regulationsapplicable to public companies in Poland. BioFund further confirmed itscommitment to comply with all relevant local legal requirementsthroughout the process and noted that the conversion should take intoaccount the appropriate USD/PLN exchange rate.

The Management Board intends to engage an independent thirdparty entityto prepare a fairness opinion confirming the market nature of thetransaction, including in respect of the share price proposed byBioFund. Following the receipt of such documents, the Management Boardintends to undertake the further actions required to implement theconversion of the financial liabilities arising from the loan intoshares of the Company, as referred to in this current report.Theissuance of shares and the conversion of debt will require the adoptionof the relevant corporate resolutions, including resolutions of theSupervisory Board and the General Meeting.